Pfizer Q2 adj EPS $0.60, revenue $13.3B; raises FY2024 guidance

PFIZER INC

2024-Q2 EPS reported $0.55 revenue$28,162,000,000

Revenues $13.3B, +2% YoY (+3% operational); non-COVID revenue grew 14% operationally.
Adjusted diluted EPS $0.60, vs $0.67 prior year; includes $1.3B one-time manufacturing optimization costs.
Raised FY2024 revenue guidance to $59.5-$62.5B (from $58.5-$61.5B) and adjusted EPS to $2.45-$2.65 (from $2.15-$2.35).
Launched Manufacturing Optimization Program targeting ~$1.5B cost savings by end of 2027; one-time costs ~$1.7B.
CSO Dr. Mikael Dolsten to depart; successor search underway.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.